Genmab became a publicly traded company in 2000. Genmab’s ordinary shares are listed on Nasdaq Copenhagen under the symbol GMAB, and it is a member of the OMX Nordic Large Cap Index, the OMX Copenhagen Benchmark Index and the OMX Copenhagen 25 Index (OMXC25). Genmab’s ID code/ISIN is DK0010272202. In July 2019, Genmab’s American Depositary Shares issued pursuant to its ADR program were also listed in the United States on the Nasdaq Global Select Market under the symbol GMAB and are part of the NASDAQ Biotechnology Index (Nasdaq: NBI).
Genmab has approximately 79,000 registered shareholders. There are 66,074,535 shares outstanding. Each share has a nominal value of DKK 1, resulting in a share capital of DKK 66,074,535.
Genmab is headquartered in Copenhagen, Denmark and its main research activities are in Utrecht, the Netherlands. Genmab has development and administrative teams in both Copenhagen, Denmark and Princeton, NJ, USA and a regional office in Japan.
Genmab has four subsidiaries: Genmab B.V. and Genmab Holding B.V. in the Netherlands, Genmab US, Inc. in the United States and Genmab K.K. in Japan.
Genmab has more than 2,000 full time employees. Employees are Genmab’s most important resource and we strive to attract and retain the most qualified people to fulfil our core purpose. Genmab’s goal is to develop and retain value in our own products which could one day transform cancer treatment. At Genmab, our core purpose, together with our core values, guides and inspires employees in their everyday work.
To access our Diversity Policy click here.
Genmab develops antibody therapeutics. Genmab's main focus is on products that can be used to treat cancer. To read more about the company's products in clinical development please visit the Pipeline page.
Two Genmab therapies have been granted accelerated approval in the U.S. Tivdak® (Tisotumab Vedotin-tftv), an antibody-drug conjugate and Epkinly (epcoritamab-bysp), a T-cell engaging bispecific antibody.
In addition, there are six approved therapies incorporating Genmab innovation and owned by Genmab partners: DARZALEX® (daratumumab), Kesimpta® (ofatumumab), TEPEZZA® (teprotumumab-trbw), RYBREVANT® (amivantamab-vmjw), TECVAYLI® (teclistamab) and TALVEY® (talquetamab). Read more about these products on the Pipeline page.
Yes, Genmab has a number of products in clinical and pre-clinical development. Additionally, numerous products are under development by our partners that incorporate Genmab’s technology or innovation. Refer to The Pipeline page for more information.
You can find our interim financial reports and annual reports in the Financial reports section of this website.
We use our in-depth expertise in antibody biology to create and develop differentiated, next-generation antibody products for the treatment of cancer. Our research and innovation function consist of a strong antibody discovery engine connecting our innovative antibody platform technologies with our robust target and disease biology knowledge. This synergy continues throughout our fully integrated R&D organization where our creations enter clinical development.
We use our proprietary antibody technology platforms to create novel antibody-based therapeutics, our technologies include:
- DuoBody® platform to develop bispecific antibodies.
- HexaBody® technology to induce formation of hexamers (clusters of six). It is designed to increase the potency of antibodies while retaining their regular structure and specificity.
- DuoHexaBody® platform combines the dual targeting of HexaBody technology with increased potency of HexaBody technology to create bispecific antibodies with enhanced target-mediated hexamerization.
- HexElect® platform combines two co-dependently acting HexaBody molecules, to introduce selectivity while maximizing therapeutic potency.
To generate diverse libraries of high quality and functional antibodies, we also use or license other technologies including antibody-drug conjugates and mRNA platforms. Our research and development teams have established a streamlined process to coordinate the activities of product discovery, pre-clinical testing, manufacturing, clinical trial design and execution, and regulatory submissions across Genmab’s international operations.
We are committed to build a sustainable organization that meets environmental, social and governance (ESG) criteria of relevance to our business operations. Our non-financial reporting can be found in our Annual Report, Corporate Responsibility Report and our SASB ESG DATA TABLES 2021. As the reporting of sustainability metrics continues to evolve over the years, Genmab has and will continue to adapt and improve its metrics and disclosures. In 2020, Genmab embarked upon a more focused, business-driven Corporate Social Responsibility (CSR) strategy to steer our efforts and build a foundational CSR program. A key part of this effort included our commitment to three United Nations Sustainable Development Goals (SDGs) that were most closely aligned with our business and that our teams can positively impact. We have adopted the frameworks by the Sustainability Accounting Standards Board (SASB) and Task Force on Climate-Related Financial Disclosures (TCFD) and will follow their guidelines to disclose critical measurements on the environment, society and governance of relevance to our business operations.
Given the tremendous changes and evolution of the company- including but certainly not limited to our commercialization focus, we have updated our code to better support and reflect the needs of Genmab now and into the near future.
Our new Genmab Code of Conduct - Our Values in Action engages our people by linking their everyday roles and functions directly to our core values, and what it means to be part of the Genmab organization. The code now includes articulation of 19 key Company standards - with hyperlinks to global polices and guidance, as well as decision tools to enable our people facing challenging business or ethical dilemmas to make risk-intelligent decisions.
Click here to access our new Code of Conduct.
We are building a pipeline of 1st –in-class / best-in-class products to meet our goal to develop products that will make a real difference to cancer patients compared to current therapies. In order to do this our priorities are to advance our product pipeline by accelerating development of potential “next winners,” invest in our promising early stage portfolio, innovative technologies and new capabilities. We also need to keep and maintain a strong capital position to ensure investor and creditor confidence. Therefore, at this stage we do not plan to return capital to investors via dividends.
To ensure compliance with the notification obligation set out in the EU Market Abuse Regulation, Genmab has adopted internal rules on the possession and handling of inside information and with respect to our board of directors’, registered managers’ and employees’ dealings in Genmab A/S shares or in financial instruments, including ADSs listed on the Nasdaq Global Select Market.
The Board of Directors currently holds an authorization to increase the registered share capital by subscription of new shares, an authorization to issue convertible bonds, which includes a right for the lender to convert the claim to new shares, and two authorizations to issue warrants to subscribe for shares. For further details on these authorizations, please see the Articles of Association in the Governance Overview section of this website.
PricewaterhouseCoopers is Genmab's auditor.
Yes, Genmab has established a sponsored Level 3 ADR program. American Depositary Shares issued under the ADR Program are listed on the Nasdaq Global Select Market in the United States under the symbol GMAB. Click here for more information.